Fennec Pharmaceuticals Inc.
FRX.TOTSXHealthcare● Active
$12.44
$-0.28(-2.20%)
Market Cap$355535511
P/E Ratio—
52W High$14.24
52W Low$7.59
Fennec Pharmaceuticals Inc.（FRX.TO）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · FRX.TO · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($9.91M) | ($0.44M) | ($16.05M) | ($23.71M) | ($17.35M) |
| Depreciation & Amort. | $0.00M | $0.80M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $0.00M | $5.06M | $5.35M | $4.22M | $4.01M |
| Change in Working Capital | ($15.09M) | $16.94M | ($6.78M) | $1.10M | ($0.93M) |
| Net Cash from Operations | ($14.67M) | $26.98M | ($17.14M) | ($18.06M) | ($14.22M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($0.18M) | ($0.08M) | ($0.19M) | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($19.82M) | ($13.00M) | $5.00M | $19.93M | $5.00M |
| Net Cash from Financing | $25.01M | ($13.62M) | $6.64M | $20.73M | $4.98M |
| Free Cash Flow | |||||
| Free Cash Flow | ($14.67M) | $26.98M | ($17.14M) | ($18.06M) | ($14.22M) |
| FCF Margin %(computed) | -32.30% | 56.75% | -80.67% | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Fennec Pharmaceuticals Inc.
关于Fennec Pharmaceuticals Inc.（FRX.TO）现金流量表
Fennec Pharmaceuticals Inc. 2025财年经营活动现金流($0.01B)，自由现金流($0.01B)（FCF利润率-32.30%），资本支出$0.00B。
常见问题
FRX.TO · 4 问Fennec Pharmaceuticals Inc. 2025财年自由现金流($0.01B)，同比down154.4%。
FRX.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10